The influences of obesity in laparoscopic and open distal gastrectomy patients for early gastric cancer

Running title: Surgery for Obese Gastric Cancer Patients

Kentaro Maejima¹², Nobuhiko Taniai², Hiroshi Yoshida³

¹Department of Surgery, Hasuda Hospital, Saitama, Japan
²Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan
³Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan

¹-1662 Negane, Hasuda city, Saitama 349-0131, Japan
²-396 Kosugityo, Nakahara-ku, Kawasaki city, Kanagawa 211-8533, Japan
³1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan

TEL: 048-766-8111 FAX:048-766-8110 E-mail:ken3363-attacker@nms.ac.jp
Abstract

Background: A recent increase in the number of surgeries performed on obese patients has raised several issues. In this study, we examined the effects of obesity on laparoscopic and open distal gastrectomy.

Methods: A total of 262 patients with gastric cancer (cStageI) who underwent distal gastrectomy were classified into open distal gastrectomy (ODG) (145 patients) and laparoscopic distal gastrectomy (LDG) (117 patients) groups. According to their body mass index (BMI), they were subdivided into obese (BMI ≥ 25) and non-obese patients (BMI < 25) to examine the duration of surgery, blood loss, the number of lymph node dissections, postoperative hospital stay, and incidence of postoperative complications.

Results: The duration of surgery was longer and blood loss was higher for obese patients than for non-obese patients in both groups. The results for these two endpoints were significantly reduced in the LDG group than in the ODG group both in obese and non-obese patients. Furthermore, the number of lymph nodes dissected tended to be higher in the LDG group than in the ODG group in obese patients. Postoperative hospital stay was not significantly different between obese and non-obese patients in both groups, but was significantly shorter in the LDG group than in the ODG group regardless of the body weight. The incidence of postoperative complications was significantly higher in obese
patients than in non-obese patients, although the difference between the groups was not significant.

**Conclusions:** These findings indicate that LDG may be useful for obese patients with cStage I gastric cancer.

**Key words:** obesity, gastric cancer, laparoscopic surgery
Introduction

In Japan, the number of obese patients has been increasing every year owing to Westernization of dietary habit, stable food supply, and popularization of fast food\(^1\). Patients with gastric cancer generally experience emaciation; however, the number of obese patients who develop gastric cancer has recently been increasing\(^1\). During surgery, maintaining the visual field is difficult and bleeding easily occurs. Laparoscopic distal gastrectomy (LDG) is becoming the standard surgical procedure for cStageI gastric cancer. However, laparoscopically assisted surgery is quite challenging in obese patients. In the present article, we examined the effects of obesity on LDG and open distal gastrectomy (ODG).

Materials and Methods

Patients

We included 262 patients with gastric cancer (cStageI) who underwent distal gastrectomy between January 1996 and June 2014 and classified them into the ODG (145 patients) and LDG (117 patients) groups (ODG and LDG have been initiated since 1996 and 2005, respectively). According to their body mass index (BMI), they were subdivided into obese (BMI \(\geq 25\)) and non-obese (BMI < 25) groups to examine the duration of surgery, blood loss, number of lymph nodes dissected, postoperative hospital stay, and incidence of postoperative complications. Since these endpoints were evaluated using patient data obtained >20 years ago, pStage was classified based on the Japanese Classification of
Gastric Carcinoma (13th edition) to maintain consistency and accuracy.

**Statistical analysis**

All statistical analyses were analyzed with the JMP statistical software program (SAS, Cary, NC, USA). For group comparison, $\chi^2$ test was used. Also we used the Wilcoxon rank sum test to analyze continuous variables. P values of $<0.05$ were determined to be statistically significant.

**Informed consent**

All patients were informed about their treatment options. No treatment has been given without prior informed consent. The research protocol complied with the ethical guidelines established by the Declaration of Helsinki and was approved by the institutional review board of Hasuda Hospital.

**Results**

Patient characteristics of the LDG and ODG groups are shown in Table 1 and Table 2, respectively. Each item was compared between the obese and non-obese patients. BMI significantly differed between the obese and non-obese patients both in the LDG and ODG groups. In the LDG group, the number of men and the prevalence of diabetes and hypertension were significantly higher in the obese patients than in the non-obese patients. In the ODG group, only BMI showed a significant difference.
The duration of surgery was longer in the obese patients (LDG, 260.8 minutes; ODG, 267.6 minutes) than in the non-obese patients (LDG, 230.0 minutes; ODG, 228.0 minutes) \( (p < 0.05) \). In the LDG group, blood loss was greater for the obese patients (134.0 g) than for the non-obese patients (77.7 g) \( (p < 0.05) \), and a similar tendency was observed in the ODG group (obese group [592.0 g] vs. non-obese [446.5 g]) \( (p < 0.01) \). Blood loss was significantly reduced in the LDG group than in the ODG group regardless of body weight \( (p < 0.01) \). Regarding the number of lymph nodes dissected, no significant difference was observed between the obese (26.5) and non-obese (28.2) patients in the LDG group, but it was significantly lower in the obese patients (13.0) than in the non-obese patients (30.5) in the ODG group \( (p < 0.05) \). Regarding the number of lymph nodes dissected, obese patients was higher in the LDG group than in the ODG group \( (p = 0.08) \). The length of hospital stay was not significantly different in the LDG group (obese [17.2 days] and non-obese [13.5 days] patients) and in the ODG group (obese [21.4 days] and non-obese [22.3 days] patients) \( (p < 0.01) \) but was significantly shorter in the LDG group than in the ODG group regardless of body weight. The incidence of postoperative complications (i.e., those with Clavien–Dindo \( \geq \) Grade 2) was higher in the obese patients (16.0%) than in the non-obese patients (4.3%) in the LDG group \( (p < 0.05) \). Such a tendency was observed in the ODG group (obese...
group [21.7%] vs. non-obese group [10.7%]) \((p = 0.17)\) (Table 3). There were no cases of reoperation due to postoperative complications. No surgery-related deaths were observed.

**Discussion**

In Japan, an increase in the proportion of obese patients has been associated with an increased number of surgeries for these patients. Such a tendency is also observed in the field of gastric cancer surgery in which advancements in diagnostic technologies have enabled early detection. Surgery for obese patients poses several issues, such as difficulty in surgical manipulation and the onset of postoperative complications. Our literature search was performed in Pubmed using the keywords “gastric cancer surgery” and “obesity.” Studies relevant to our research and similar variables were few. Among the obese patients, visceral fat obesity is more closely associated with glucose tolerance, lipid metabolism abnormality, hypertension, and arteriosclerosis than subcutaneous fat obesity\(^2\). Therefore, if these diseases are not identified preoperatively, adequate caution should be exercised, particularly in patients with visceral fat obesity. The recent advancements in diagnostic technologies have enabled the detection of early-stage cancer, thereby increasing the likelihood of surgery in obese gastric cancer patients with excess visceral fat. The effects of obesity on surgery for gastric cancer patients have been
evaluated, indicating that the obese patients face several disadvantages when compared with the non-obese patient. Longer duration of surgery, greater volume of blood loss, and higher incidence of postoperative complications, such as pancreatic fistula, intraabdominal infection, and suture failure are some of the issues faced by obese patients.

Recently, several studies have also evaluated whether laparoscopically assisted gastrectomy is useful for obese patients. Shin et al. reported that although such a procedure can be safely performed on these patients, because of the technical difficulties in lymph node dissection, it should be reserved for early-stage cancers. BMI is commonly used as an index of obesity because it can be easily calculated based on height and body weight. However, the correlation between BMI and physique differs in some cases; thus, BMI does not accurately reflect obesity risk. Diagnostic criteria for obesity proposed by the Japan Society for the Study of Obesity include visceral fat area (VFA) in addition to BMI. VFA is determined by abdominal computed tomography at the umbilical level, and patients with ≥100 cm² of VFA are categorized as having visceral fat obesity. Several studies have evaluated surgical risk using BMI and VFA. Yoshikawa et al. documented that VFA was more favorable than BMI to predict blood loss during LDG and postoperative complications. In addition, Tanaka et al. described that VFA was more
favorable than BMI to predict the onset of pancreatic fistula after total gastrectomy\textsuperscript{12}. The subsequent study revealed that it was uncertain as to whether VFA measurements determined by abdominal computed tomography outperform BMI in predicting the surgery risk for obese patients with gastric cancer\textsuperscript{1}. Based on these reports, BMI, which can be easily calculated at any medical institution, may currently be more reliable than VFA.

Endoscopic surgery has seen rapid advancements owing to improvements in surgical techniques, formulation of surgical modality, and development of surgical instruments. In terms of surgery for gastric cancer, Kitano et al. first reported LDG in 1994\textsuperscript{13}. Since, then, the number of patients receiving LDG has steadily increased, and the superiority of this procedure over open surgery has been established\textsuperscript{14–32}. The 2014 guidelines for endoscopic surgery have classified LDG under level B (i.e., it is recommended) for gastric cancer patients with cStage\textsuperscript{33}. According to the 12\textsuperscript{th} nationwide survey of endoscopic surgery in Japan, gastric surgery was laparoscopically performed on 9168 patients in 2013, accounting for 34.0\% of all gastric surgeries. With the number of laparoscopically assisted gastric surgery procedures increasing every year\textsuperscript{34}, this type of surgery has been standardized. Currently, a clinical trial uses this procedure and has achieved favorable short-term results (i.e., noninferiority to open surgery) in patients with advanced gastric
cancer. Thus, it is likely that indications for laparoscopically assisted gastric surgery will be expanded in the future\textsuperscript{35}.

The duration of surgery was longer and blood loss was greater in the obese patients than in the non-obese patients; however, the blood loss may be reduced through the use of LDG in the obese patients.

The number of lymph nodes dissected was lower in the obese patients in the ODG group. The use of LDG may increase such numbers in the obese patients.

Postoperative hospital stay was similar between the obese and non-obese patients; however, it was significantly shorter in the LDG group than in the ODG group.

The incidence of postoperative complications was higher in the obese patients than in the non-obese patients. However, in this study, although there was no statistically significant difference, obese cases tended to have slightly lower lymph node dissection than non-obese cases. It is necessary to consider how this will affect long-term results in the future.

In conclusion, LDG may be useful for obese patients with cStageI gastric cancer for short-term results.

**Conflict of Interest:** All authors declare that they have no conflicts of interest.
References

1. Higa T, Nakasone N, Tamashiro A et al. Human assisted translation: Influence of obesity on gastric cancer surgery - Evaluation by visceral fat area measurement using preoperative abdominal CT. Medical Journal of Naha City Hospital. 2012;4:11-18.

2. Yoshizumu T. The relationship between the criteria for metabolic syndrome and the evaluation of abdominal fat distribution measured by CT scan. Radiol Technol. 2007 March 1;63(3):276-84.

3. Kodera Y, Ito S, Nakao A, et al. Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma. Hepatogastroenterol. 2004 July 1;51(58):1225-8.

4. Kojima T, Matsui T, Uemuta T, et al. Body mass index, fat volume and outcome of laparoscopy-assisted distal gastrectomy. Jpn J Gastroenterol Surg. 2009;42(4):442-7.

5. Nobuoka D, Gotohda N, Kato Y, et al, Influence of excess body weight on the surgical outcomes of total gastrectomy. Surg Today. 2011 July 1;41(7):928-34.

6. Tokunaga M, Hiki N, Fukunaga T, et al. Effect of individual fat areas on early surgical outcomes after open gastrectomy for
gastric cancer. Br J Surg. 2009 May;96(5):496-500.

7. Sugisawa N, Tokunaga M, Tanizawa Y, et al. Intra’abdominal infectious complications following gastrectomy in patients with excessive visceral fat. Gastric Cancer. 2012 Apr;15(2):206-12.

8. Makino H, Kunisaki C, Akiyama H, et al. Effect of obesity on intraoperative bleeding volume in open gastrectomy with D2 lymph’node dissection for gastric cancer. Patient Saf Surg. 2008 Dec;2(1):7.

9. Shim JH, Song KY, Kim SN, et al. Laparoscopy—assisted distal gastrectomy for overweight patients in the Asian population. Surg Today. 2009 June;39(6):481-6.

10. Yamamoto S, Nakagawa T, Kusano S et al. Development of the automated diagnosis system CT screening for visceral obesity. MEDIX. 2004;41:15-20.

11. Yoshikawa K, Shimada M, Kurita N, et al. Visceral fat area is superior to body mass index as a predictive factor for risk with laparoscopy—assisted gastrectomy for gastric cancer. Surg Endosc. 2011 Dec;25(12):3825-30.

12. Tanaka K, Miyashiro I, Yano M, et al. Accumulation of excess visceral fat is a risk factor for pancreatic fistula formation after total
gastrectomy.  Ann Surg Oncol. 2009 Jun;16(6):1520-5.

13. Kitano S, Iso Y, Moriyama M, et al. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc. 1994 Apr 1;4(2):146-8.

14. Kitano S, Shiraishi N, Fujii K, et al. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery. 2002 Jan 1;131(1):S306-11.

15. Amaike H, Taniguchi H, Fuji N et al. Clinical analysis of laparoscopy-assisted distal gastrectomy (LADG) for the treatment of gastric cancer. Journal of Kyoto Prefectural University of Medicine. 2004;113:867-72.

16. Kojima T, Hiraguchi E, Hiraguchi E, Konishi K et al. Evaluation of laparoscopy-assisted distal gastrectomy (LADG) for the treatment of early-stage gastric cancer (in Japanese). Journal of the Medical Assoc. South Hokkaido. 2004;39:216-8.

17. Shimizu T, Nakamura S, Sawada T. Evaluation of laparoscopy-assisted distal gastrectomy (LADG) for the treatment of early-stage gastric cancer (in Japanese). The Journal of the Tottori Medical Association. 2005;33:175-80.

18. Yamaguchi K, Shibuya H, Sasaki K, et al. Clinical evaluation of laparoscopy-assisted distal gastrectomy for early gastric cancer. Tumor Res. 2005;40:37-45.

19. Kuwabara S, Katayanagi N, Matsubara H et al. Initial results of laparoscopy-assisted
distal gastrectomy (LADG) for the treatment of early-stage gastric cancer: Comparison with open distal gastrectomy (in Japanese). Niigata Medical Journal. 2006;120:270-8.

20. Suzuki S, Tominaga K, Hoshino M et al. Study of laparoscopy-assisted gastrectomy in private group hospital. Journal of Japanese College of Surgeons. 2007;32:632-7.

21. Kishimoto H, Yoshifuku S, Tsukada Y et al. Short-term outcomes of laparoscopy-assisted distal gastrectomy (in Japanese). Medical journal of Aizawa Hospital. 2009;7:9-13.

22. Suzuki T, Tanabe K, Tokumoto N et al. A study of laparoscopic assisted distal gastrectomy in our hospital. The Journal of the Hiroshima Medical Association. 2009;62:402-5.

23. Ishikawa K, Kishihara F, Fukuyama Y et al. Results of laparoscopy-assisted distal gastrectomy for the treatment of early-stage gastric cancer in our hospital (in Japanese). The Journal of the Oita Medical Association. 2009;27:10-15.

24. Kagawa S, Uno F, Gochi A, et al. Laparoscope-assisted gastrectomy for early gastric cancer: Analysis of 18 initial cases. Journal of Japanese College of Surgeons. 2009;34:151-6.
25. Murakami H, Rino Y, Yukawa N et al. Laparoscope-assisted gastrectomy in our department: 10-year results (in Japanese). Yokohama Medical Journal. 2010;61:77-81.

26. Karimata H, Nagahama M, Shimoji E et al. A Study of Laparoscopy-assisted gastrectomy in an area with few gastric cancer patients. Journal of Japanese College of Surgeon. 2010;35:707-12.

27. Takemura M, Toyokawa T, Sakurai K et al. Clinical outcomes after laparoscopic distal gastrectomy for pT1 or pT2 gastric cancer. Japanese Journal of Cancer Clinics. 2010;56:849-56.

28. Sasaki K, Yoda N, Onodera S et al. Clinical outcome of laparoscopy-assisted distal gastrectomy for early gastric cancer. Journal of Japan Surgical Association. 2011;72:1091-6.

29. Yoshimura F, Inaba K, Kawamura Y, et al. Clinical outcome and clinicopathological characteristics of recurrence after laparoscopic gastrectomy for advanced gastric cancer. Digestion 2011;83(3):184-90.

30. Yamada T, Jin Y, Maezawa Y et al. Evaluation of the safety and curative value before and after introduction of laparoscopy-assisted distal gastrectomy (in Japanese). Journal of Japanese College of Surgeons. 2012;37:673-9.
31. Nishiwa S, Watanabe A, Yoshikawa T et al. Evaluation of laparoscope-assisted distal gastrectomy for early gastric cancer (in Japanese). Medical Journal of Prefectural Nara Hospital. 2012;16:21-6.

32. Kunisaki C, Makino H, Kosaka T, et al. Surgical outcomes of laparoscopy-assisted gastrectomy versus open gastrectomy for gastric cancer: a case-control study. Surg Endosc 2012 Mar;26(3):804-10.

33. The guidelines for endoscopic surgery for qualified surgeons (in Japanese). Japan Society for Endoscopic Surgery. Special issue. 2014;11-22.

34. The 12th nationwide survey of endoscopic surgery in Japan (in Japanese). Journal of Japan Society for Endoscopic Surgery. 2014;19:525-56.

35. Inaki N, Etoh T, Ohyama T, et al. A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg. 2015 Nov;39(11):2734-41.
Figure Legends

Fig. 1. Duration of surgery in obese and non-obese patients by laparoscopic distal gastrectomy (LDG) (A) and open distal gastrectomy (ODG) (B). The median values are depicted by the horizontal line, and the lower and upper edges of the boxes depict the 25 and 75 percentiles, respectively.

The duration of surgery was longer in the obese patients (LDG, 260.8 minutes; ODG, 267.6 minutes) than in the non-obese patients (LDG, 230.0 minutes; ODG, 228.0 minutes) (p < 0.05).

Fig. 2. Blood loss in obese and non-obese patients by laparoscopic distal gastrectomy (LDG) (A) and open distal gastrectomy (ODG) (B). The median values are depicted by the horizontal line, and the lower and upper edges of the boxes depict the 25 and 75 percentiles, respectively.

In the LDG and ODG groups, blood loss was greater for the obese patients (134.0 g and 592.0 g, respectively) than for the non-obese patients (77.7 g and 446.5 g, respectively) (p < 0.05 and p < 0.01, respectively).

Fig. 3. The number of lymph nodes dissected in obese and non-obese patients by laparoscopic distal gastrectomy (LDG) (A) and open distal gastrectomy (ODG) (B). The median values are depicted by the horizontal line, and the lower and upper edges of the
boxes depict the 25 and 75 percentiles, respectively.

The number of lymph nodes dissected was not significantly different between the obese (26.5) and non-obese (28.2) patients in the LDG group. However, it was lower for the obese patients (13.0) than for the non-obese patients (30.5) in the ODG group (p < 0.05), but higher for obese patients in the LDG group than in the ODG group.

Fig. 4. Postoperative hospital stay for obese and non-obese patients after laparoscopic distal gastrectomy (LDG) (A) and open distal gastrectomy (ODG) (B). The median values are depicted by the horizontal line, and the lower and upper edges of the boxes depict the 25 and 75 percentiles, respectively.

No significant difference was observed in postoperative hospital stay between the obese (LDG, 17.2 days; ODG, 21.4 days) and non-obese (LDG, 13.5 days; ODG, 22.3 days) patients. However, it was significantly shorter in the LDG group than in the ODG group regardless of body weight.
A

Obese: 260.8 ± 63.4 min
Non-obese: 230.0 ± 54.2 min

p < 0.05

B

Obese: 267.6 ± 75.8 min
Non-obese: 228.0 ± 70.1 min

p < 0.05
**A**

Bleeding volume (g) for Obese vs. Non-obese:

- Obese: 134.0 ± 115.3g
- Non-obese: 77.7 ± 82.3g

p < 0.05

**B**

Bleeding volume (g) for Obese vs. Non-obese:

- Obese: 592.0 ± 258.5g
- Non-obese: 446.5 ± 335g

p < 0.01
A

Number of lymph node dissections

Obese: 26.5 ± 16.1
Non-obese: 28.2 ± 13.7

p = 0.45

B

Number of lymph node dissections

Obese: 13.0 ± 4.6
Non-obese: 30.5 ± 13.4

p < 0.05
**A**

Postoperative hospital stay (days)

- Obese: $17.2 \pm 11.6$ days
- Non-obese: $13.5 \pm 4.4$ days

$p = 0.61$

**B**

Postoperative hospital stay (days)

- Obese: $21.4 \pm 6.8$ days
- Non-obese: $22.3 \pm 6.5$ days

$p = 0.56$
|                                | Obese | Non-obese | p value |
|--------------------------------|-------|-----------|---------|
| **BMI**                        | 26.7±1.4 | 21.5±2.4 | <0.01   |
| **Age**                        | 67.9±10.1 | 67.5±10.3 | 0.88    |
| **Sex**                        | Male  | 21 | 57 | 0.03 |
|                                | Female | 4 | 35 |  |
| **Depth**                      | T1 | 25 | 89 | 0.23 |
|                                | T2 | 0 | 3 |  |
| **Lymph node metastasis**      | N0 | 24 | 91 | 0.17 |
|                                | N1 | 1 | 0 |  |
|                                | N2 | 0 | 1 |  |
| **Lymph node dissection**      | D1 | 17 | 44 | 0.17 |
|                                | D1+ | 8 | 47 |  |
|                                | D2 | 0 | 1 |  |
| **pStage**                     | I A | 24 | 88 | 0.55 |
|                                | I B | 1 | 2 |  |
|                                | II | 0 | 2 |  |
| **Comorbidity**                | Diabetes | 6/25 | 7/92 | 0.03 |
|                                | Hypertension | 15/25 | 33/92 | 0.03 |
|                                | Heart disease | 6/25 | 9/92 | 0.08 |
|                                | Lung disease | 0/25 | 2/92 | 0.32 |
|                         | Obese n = 23 | Non-obese n = 122 | p value |
|-------------------------|--------------|-------------------|---------|
| BMI                     | 27.2±1.7     | 21.2±2.2          | <0.01   |
| Age                     | 64.1±11.1    | 64.6±13.7         | 0.72    |
| Sex                     |              |                   |         |
| Male                    | 17           | 81                | 0.47    |
| Female                  | 6            | 41                |         |
| Depth                   |              |                   |         |
| T1                      | 23           | 122               |         |
| T2                      | 0            | 0                 |         |
| Lymph node metastasis   |              |                   |         |
| N0                      | 22           | 117               | 0.96    |
| N1                      | 1            | 5                 |         |
| N2                      | 0            | 0                 |         |
| Lymph node dissection   |              |                   |         |
| D1                      | 15           | 51                | 0.06    |
| D1+                     | 7            | 50                |         |
| D2                      | 1            | 21                |         |
| pStage                  |              |                   |         |
| I A                     | 22           | 115               | 0.78    |
| I B                     | 1            | 7                 |         |
| II                      | 0            | 0                 |         |
| Comorbidity             |              |                   |         |
| Diabetes                | 2/23         | 14/122            | 0.69    |
| Hypertension            | 7/23         | 32/122            | 0.68    |
| Heart disease           | 4/23         | 11/122            | 0.26    |
| Lung disease            | 0/23         | 1/122             | 0.56    |
|                          | Obese LDG n = 25 | Non-obese LDG n = 92 | Obese ODG n = 23 | Non-obese ODG n = 122 |
|--------------------------|------------------|----------------------|------------------|-----------------------|
| Surgical site infection  | 1                | 0                    | 3                | 3                     |
| Anastomotic leakage      | 1                | 1                    | 0                | 0                     |
| Anastomotic stenosis     | 1                | 0                    | 0                | 0                     |
| Pancreatic fistula       | 1                | 0                    | 0                | 0                     |
| Pancreatitis             | 0                | 0                    | 1                | 1                     |
| Pneumonia                | 0                | 2                    | 0                | 0                     |
| Ileus                    | 0                | 0                    | 0                | 1                     |
| Postoperative bleeding   | 0                | 0                    | 0                | 1                     |
| Others                   | 0                | 1                    | 1                | 7                     |
| **Total**                | **4 (16.0)**     | **4 (4.3)**          | **5 (21.7)**     | **13 (10.7)**         |